Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Mar 7, 2023

Keywords

ClinConnect Summary

This clinical trial is testing a special type of imaging called Al18F-PSMA-BCH PET/CT to see how well it can detect tumors that express a protein known as prostate-specific membrane antigen (PSMA). This study is focused on patients who have suspected or diagnosed cancers that show this PSMA protein, including types like prostate cancer and others. The trial is currently recruiting participants aged 18 and older, regardless of gender, who are willing to give their consent and follow the study guidelines.

If you decide to participate, you can expect to undergo the Al18F-PSMA-BCH PET/CT scan, which is a non-invasive imaging test that helps doctors see if the PSMA protein is present in your tumors. However, there are some important things to consider: individuals with serious health issues, such as major heart or lung problems, or those who are pregnant or breastfeeding cannot participate. Also, if you have a fear of small spaces (claustrophobia), this trial may not be for you. Your involvement will help researchers learn more about the effectiveness of this imaging technique in identifying specific types of cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.
• • 2. Age is 18 or older; No gender limitation.
• • 3. Signed the informed consent.
• • 4. Willing and able to cooperate with all projects in this study.
• Exclusion Criteria:
• • 1. Patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc
• • 2. Claustrophobia.
• • 3. Pregnant or lactation women.
• • 4. Received experimental drug or device within 1 month.